Chris Boerner, Board Chair and Chief Executive Officer at Bristol Myers Squibb, shared on LinkedIn:
“Bristol Myers Squibb has spent the last few years digging into how Artificial Intelligence can transform the future of drug discovery – and early results are giving us the confidence to dig even deeper.
Today, we announced the expansion of our collaboration with NVIDIA to deploy DGX Vera Rubin NVL72 systems, giving BMS the most powerful and energy-efficient AI setup of its kind in life sciences.
Through our ‘Predict First‘ approach, AI has enabled BMS researchers to validate the design of every small molecule program – and the majority of large molecule programs – before anyone even steps into the lab.
This expansion will enable us to go even further with more computing power, more sophisticated models and a system that gets smarter with every experiment and clinical readout.
Coupled with our recent strategic agreement with Anthropic, BMS is continuing to build an AI ecosystem that helps unleash data, unlock speed and efficiency across R&D, and ultimately get the right medicine to the right patient faster.
The science has always been extraordinary.
Now we have the technology to match our ambition, and no one is better positioned to lead than BMS.”
Other articles about Bristol Myers Squibb and AI on OncoDaily.
